LIFE on Nasdaq
Life Technologies
Logo: Unknown author Unknown author, Public domain, via Wikimedia Commons5
Biotech company
Life Technologies Corporation was a biotech company founded in November 2008 through a US $6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees and owned more than 3,600 licenses and patents.3 From Wikipedia, CC BY-SA 4.0
$38.38 down 0.58 (1.50%)Price as of Oct 15, 2026 at 17:33 UTC
Last updated Oct 16, 2026.
Overview
Compare with Goosehead Insurance, Inc., eHealthInsurance or Waterdrop Inc., or pick any stock.
- TickerLIFE on Nasdaq1
- IndustryInsurance Agents, Brokers & Service1
- HeadquartersCarlsbad1
- Websitewww.lifetechnologies.com
- Legal formDelaware corporation1
- Incorporated inDE7
- Business address1606 Headway Circle, #9013, Austin, Tx 787547
- Filer category, Emerging growth company7
See how the biggest companies compare on our leaderboards
Life Technologies Corporation was a biotech company founded in November 2008 through a US $6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees and owned more than 3,600 licenses and patents.3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue2¢$6.7M
- Other costs79¢$305.1M
- Income tax1¢$4.6M
- Profit18¢$71.2M
Out of $387.6M in revenue.6
Where each dollar of operating cash went, fiscal 2025
- Capital spending4¢$1.5M
- Kept or used elsewhere96¢$34.7M
Out of $36.2M of cash from operations.6
Financial statements
Every line of the income statement in the latest annual report, as filed.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Commission | $387.6M | $254.9M |
| Total revenue | $387.6M | $254.9M |
| Sales and marketing | $229.3M | $148.7M |
| General and administrative | $39.6M | $22.4M |
| Technology (exclusive of amortization) | $33.6M | $23.1M |
| Cost of revenue | $6.7M | $6.5M |
| Depreciation and amortization | $5.4M | $5.4M |
| Total costs and expenses | $314.7M | $206.2M |
| Income from operations | $72.9M | $48.7M |
| Interest expense | -$3.2M | -$595.0K |
| Interest income | $5.8M | $5.6M |
| Other income, net | $161.0K | $185.0K |
| Total other income (expense), net | $2.8M | $5.2M |
| Net income before income tax expense | $75.7M | $53.9M |
| Income tax expense | -$4.6M | -$5.1M |
| Net income | $71.2M | $48.8M |
| Change in unrealized gain (loss) on marketable securities | $253.0K | -$121.0K |
| Unrealized foreign currency translation loss | -$329.0K | -$199.0K |
| Total other comprehensive income (loss) | -$76.0K | -$320.0K |
| Comprehensive income | $71.1M | $48.5M |
| Basic net income per share | $4.31 | $3.05 |
| Diluted net income per share | $1.22 | $0.85 |
| Weighted-average shares used in computing basic net income per share | 16.5M shares | 16.0M shares |
| Weighted-average shares used in computing diluted net income per share | 58.4M shares | 57.6M shares |
Every line of the balance sheet in the latest annual report, as filed.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and Cash Equivalent | $91.1M | $35.1M | |
| Short Term Investments | $34.9M | $68.3M | |
| Accounts receivable, net | $36.5M | $30.3M | |
| Commissions receivable-current, net | $28.8M | $15.1M | |
| Prepaid and other current assets | $54.6M | $26.1M | |
| Total current assets | $245.8M | $174.8M | |
| Commissions receivable, net | $224.2M | $173.1M | |
| Property and equipment, net | $8.2M | $7.4M | |
| Operating lease right-of-use assets | $2.2M | $2.5M | |
| Goodwill | $2.2M | $2.2M | |
| Acquired intangible assets, net of amortization | $662.0K | $221.0K | |
| Long Term Investments | $31.5M | $35.0M | |
| Other long-term assets | $574.0K | $558.0K | |
| Total long-term assets | $269.5M | $221.1M | |
| Total assets | $515.3M | $395.9M | |
| Accounts Payable | $55.1M | $24.3M | |
| Accrued expenses | $39.2M | $19.2M | |
| Liabilities related to sale of commissions receivable-current | $11.8M | $9.4M | |
| Operating lease liabilities-current | $1.1M | $753.0K | |
| Other current liabilities | $6.0M | $13.9M | |
| Total current liabilities | $113.2M | $67.6M | |
| Liabilities related to sale of commissions receivable-non-current | $12.5M | $24.2M | |
| Operating lease liabilities-non-current | $1.2M | $1.9M | |
| Deferred tax liability | $8.5M | $3.9M | |
| Other long-term liabilities | $0 | $1.5M | |
| Total long-term liabilities | $22.3M | $31.4M | |
| Total liabilities | $135.5M | $99.0M | |
| Redeemable convertible preferred stock, par value $0.0001 - 37,400 and 37,228 shares authorized, 37,228 issued, and outstanding (liquidation preference of $404,801) as of December 31, 2025 and December 31, 2024 | $404.0M | $404.0M | |
| Common stock, $0.0001 par value, 1,040,000 and 62,390 shares authorized, 16,647 and 16,032 issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $2.0K | $2.0K | |
| Additional paid-in capital | $79.0M | $67.0M | |
| Accumulated other comprehensive loss | -$554.0K | -$478.0K | |
| Accumulated deficit | -$102.5M | -$173.7M | |
| Total stockholders' deficit | -$24.1M | -$107.2M | -$159.2M |
| Total liabilities, redeemable convertible preferred stock and stockholders' deficit | $515.3M | $395.9M | |
| Redeemable convertible preferred stock, par value | $0 | $0 | |
| Redeemable convertible preferred Shares Authorized | 37.4M shares | 37.2M shares | |
| Redeemable convertible preferred Shares Issued | 37.2M shares | 37.2M shares | |
| Redeemable convertible preferred Shares Outstanding | 37.2M shares | 37.2M shares | |
| Liquidation Value | $404.8M | $404.8M | |
| Common stock par value | $0 | $0 | |
| Common stock shares authorized | 1.0B shares | 62.4M shares | |
| Common Stock, Shares, Issued | 16.6M shares | 16.0M shares | |
| Common stock share outstanding | 16.6M shares | 16.0M shares |
Every line of the cash flow in the latest annual report, as filed.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net income | $71.2M | $48.8M |
| Total deferred expense | $4.6M | $3.9M |
| Depreciation and amortization | $5.4M | $5.4M |
| Non-cash interest expense | $3.2M | $595.0K |
| Accretion (amortization) of discounts and premium, investments | -$1.2M | -$3.1M |
| Stock-based compensation expense | $10.6M | $3.2M |
| Operating lease right-of-use asset amortization | $903.0K | $42.0K |
| Unrealized foreign currency translation | -$303.0K | -$199.0K |
| Prepaid and other assets | -$21.4M | -$24.3M |
| Accounts payable | $30.6M | $12.7M |
| Accounts receivable | -$11.2M | -$13.6M |
| Commissions receivable | -$13.7M | -$9.2M |
| Long-term commissions receivable | -$51.1M | -$53.9M |
| Accrued expenses | $18.9M | $7.3M |
| Other current liabilities | -$8.7M | $12.4M |
| Other long-term liabilities | -$1.5M | -$1.0M |
| Net cash provided by (used in) operating activities | $36.2M | -$10.9M |
| Purchase of property and equipment | -$1.5M | -$776.0K |
| Purchase of domain name | -$500.0K | -$250.0K |
| Purchase of investments | -$66.7M | -$154.7M |
| Proceeds from maturity of investments | $99.9M | $145.0M |
| Sales of investments | $5.0M | $13.4M |
| Investment in software development costs | -$4.3M | -$3.6M |
| Net cash provided by (used in) investing activities | $31.9M | -$896.0K |
| Proceeds from liabilities related to sale of commissions receivable | $5.0M | $23.6M |
| Repayment of liabilities related to sale of commissions receivable | -$12.0M | -$1.9M |
| Proceeds from exercise of stock options and warrants | $1.1M | $209.0K |
| Payment of deferred offering costs | -$6.2M | $0 |
| Net cash provided by (used in) financing activities | -$12.0M | $21.9M |
| Net increase in cash and cash equivalents | $56.0M | $10.1M |
| Effect of exchange rates on cash | -$27.0K | $2.0K |
| Capitalized Property And Equipment Costs In Accounts Payable | $26.0K | $44.0K |
| Cash paid for income taxes | $1.8M | $517.0K |
| Operating lease liabilities arising from obtaining operating lease right-of-use assets | $596.0K | $2.7M |
| Stock-based compensation capitalized as software development costs | $305.0K | $143.0K |
| Deferred offering costs in accounts payable and accrued expenses | $1.1M | $0 |
Subsidiaries and ownership
Parent company
- Thermo Fisher Scientific Inc. since Feb 3, 2014
From Wikidata.1
Acquisitions
Between its formation in 2008 and its acquisition by Thermo Fisher Scientific in 2014, Life Technologies Corporation was an independent multinational corporation based in Carlsbad, California, United States.
In 2013, they launched a project called Claritas Genomics in partnership with Boston Children's Hospital. With Children's as a major shareholder, Claritas Genomics merged the knowledge, resources, and employees of the Genetic Diagnostic Lab at the Boston hospital, a CLIA-certified facility that provided more than 100 genetic tests, including numerous specific diagnostics created at Boston Children's. It also made use of the Ion Proton Sequencer from Life Technologies, a precise benchtop device that might be scaled for widespread use in new assays.
Later, in 2013, Thermo Fisher agreed to buy Life Technologies for $13.6 billion.
From Wikipedia’s article on Life Technologies, shared under CC BY-SA 4.0.8
Controversies and legal
Legal disputes
A court case involving Life Technologies (as the former Applera Corp) ended in January 2014, as the Connecticut District Court penalized Life Technologies Corp over $60 million for patent infringements by its parent companies prior to the merger. The jury awarded $48 million in royalty damages to the plaintiffs Enzo Biochem, Inc, Enzo Life Sciences, and Yale University.
From Wikipedia’s article on Life Technologies, shared under CC BY-SA 4.0.8
Timeline
Recent filings
- Oct 14, 2026144
- Oct 9, 20268-K
- Sep 18, 20264
- Sep 18, 20264
- Sep 18, 2026144
- Sep 17, 2026144
- Sep 17, 2026144
- Sep 16, 20268-K
- Sep 16, 2026144
- Sep 10, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
- Sep 10, 20264
- Aug 25, 20264
- Aug 25, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
- Aug 21, 2026144
- Aug 21, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitewww.lifetechnologies.com1
- WikipediaLife Technologies
- WikidataQ1824441
- SEC EDGARCIK 1788451
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataLife Technologies on Wikidata
- 2
- 3WikipediaLife Technologies on Wikipedia
- 4Yahoo FinanceLIFE quote
- 5
- 6
- 7
- 8
- 9
- 10